Just caught Novo Nordisk's 2024 guidance update and those 23/27 percentage growth targets are pretty solid. They're looking at 23-27% sales growth in constant exchange rates, with operating profit tracking at 21-27%. That's the kind of range most pharma companies would be happy with. The currency headwind is worth noting though - if you're looking at Danish kroner numbers, you'd see about 1-2 percentage points lower depending on whether you're tracking sales or profit. Interesting to see how they're positioning themselves after all the GLP-1 buzz. The 23/27 percentage spread gives them some breathing room either way. Worth keeping an eye on how they actually execute against these targets.